EGFR-IN-8

EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC In Vitro EGFR-IN-8 (0-20 μM; 24-72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97 cells at different time intervals, with IC 50 values ranging from 0.3 to 0.6 μM and 0.2-0.5 μM after 48 and 72 h of treatment respectively. EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A549, PC9, H1975, CL68, and CL97 cells Concentration: 0-20 μM Incubation Time: 24 hours, 48 hours, 72 hours Result: Showed inhibitory effects on different cells. Western Blot AnalysisCell Line: A549, PC9, H1975, CL68, and CL97 cells Concentration: 0-0.6 μM Incubation Time: 48 hours Result: Decreased EGFR and c-Met expression. In Vivo EGFR-IN-8 (oral gavage; 50 and 150 mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice H1975 xenograft tumor model Dosage: 50 and 150 mg/kg Administration: Oral gavage; 50 and 150 mg/kg; once daily; 20 days Result: Inhibited H1975 xenograft tumor growth. Form:Solid IC50& Target:EGFR,c-Met

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet